Spinocerebellar Ataxia (SCA) Clinical Trials and Treatments

The spinocerebellar ataxias (SCAs) are a large group of autosomal dominant neurodegenerative disorders characterized by progressive cerebellar dysfunction. The most common mechanism involves polyglutamine (polyQ) repeat expansions in specific genes, leading to toxic protein accumulation and neuronal death. SCA1, SCA2, SCA3 (Machado-Joseph disease), SCA6, and SCA7 are polyQ expansion disorders and account for the majority of cases.

The most common symptoms of Spinocerebellar Ataxia include Progressive difficulty with walking and balance (gait ataxia), Slurred or scanning speech (dysarthria), Difficulty with fine motor tasks and hand coordination, Abnormal eye movements (nystagmus, slow saccades), Dysphagia (difficulty swallowing) in advanced stages, among others. Collectively about 1-5 per 100,000 people; SCA3 (Machado-Joseph disease) is the most common subtype worldwide. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Spinocerebellar Ataxia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research into SCA is advancing on multiple fronts, with considerable focus on halting the underlying disease mechanisms. Biohaven's troriluzole missed its main goal in the placebo-controlled part of its Phase 3 study.

As of October 21, 2026, no current FDA drug label names Spinocerebellar Ataxia as a condition the drug treats.

Most common spinocerebellar ataxias are caused by expanded CAG trinucleotide repeats in specific genes, producing abnormally long polyglutamine tracts in the resulting proteins. These elongated proteins misfold and aggregate, forming toxic intranuclear inclusions that damage cerebellar Purkinje cells and connected brainstem and spinal cord neurons. SCA1, SCA2, SCA3 (Machado-Joseph disease), SCA6, SCA7, and SCA17 all follow this polyglutamine expansion mechanism, though each gene affects different protein functions and neural circuits. Other subtypes work differently. SCA27B, for example, is caused by a GAA repeat expansion in a non-coding part of the FGF14 gene. The cerebellum coordinates movement, balance, and speech, so its progressive degeneration produces the hallmark gait ataxia, dysarthria, and oculomotor dysfunction.

Spinocerebellar ataxias are caused by mutations in over 40 different genes, with the most common subtypes involving polyglutamine (CAG) repeat expansions. Genetic testing through targeted repeat expansion panels or comprehensive ataxia gene panels is the primary diagnostic tool and is required for enrollment in subtype-specific trials like VO659 (SCA1/SCA3) and ARO-ATXN2 (SCA2). Key genes include ATXN1 (SCA1), ATXN2 (SCA2), ATXN3/MJD (SCA3, Machado-Joseph disease), CACNA1A (SCA6), and ATXN7 (SCA7). CAG repeat length correlates with age of onset and severity, and genetic anticipation means successive generations may develop symptoms earlier. Labs offering SCA panels include GeneDx, Invitae, and Prevention Genetics. Presymptomatic testing is available for at-risk family members.

Eligibility for Spinocerebellar Ataxia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Spinocerebellar Ataxia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Spinocerebellar ataxia clinical trials generally allow continuation of symptom-management medications (baclofen, gabapentin, SSRIs, buspirone) as long as the regimen has been stable for 28 to 42 days before enrollment. The primary exclusion patterns involve investigational agent washout (30 to 90 days), strong CYP3A4 inhibitors or inducers (relevant in omaveloxolone-related studies), prior gene therapy or ASO exposure, and QT-prolonging medications in trials with cardiac safety monitoring. Trial Friend's medication conflict checker scans each trial's exclusion criteria against common SCA medications including anti-seizure drugs, muscle relaxants, antidepressants, and investigational therapies. The checker flags the specific drug, the trial's exclusion language, and a confidence level so you can discuss timing with your neurologist.

Key questions to ask your neurologist about SCA clinical trials include: Are there ASO or gene-silencing trials specifically designed for my SCA subtype and mutation? What genetic testing would confirm my exact repeat length and determine which trials I qualify for? How do current trial approaches differ for early symptomatic versus presymptomatic patients? Would I need to stop any current medications, and for how long, before enrolling? What biomarkers or imaging assessments (MRI volumetrics, neurofilament light chain) would track response to experimental therapies? How does my SARA score or disease stage affect which trials are realistic options?